DelSite Inc. (DSII.OB) said that it has terminated its manufacturing operations at its Irving, Texas facility. Continuation of non-manufacturing domestic operations and manufacturing at its Costa Rican plant is contingent on new funding.
In addition, the company stated that its unit, DelSite Biotechnologies Inc., received the FDA approval to initiate a phase I clinical study of the company's lead product candidate GelVac nasal powder H5N1 (bird flu) influenza vaccine.
Once developed, this vaccine system can significantly improve and reduce the cost of individual vaccines as well as reduce the cost of stockpiling strategic vaccines, the company noted.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.